The latest option combines empagliflozin and metformin hydrochloride.
Another combination therapy for type 2 diabetes mellitus (T2DM) has entered the US market with FDA’s approval August 27, 2015, of Synjardy, which includes an SGLT2 inhibitor, empagliflozin, and metformin hydrochloride.
Synjardy is the third therapy that includes empagliflozin; which was approved as a monotherapy and is sold as Jardiance, and as Glyxambi, which combines the SGLT2 inhibitor with linagliptin, a DPP-4 (dipeptidyl peptidase-4) inhibitor.
The new combination therapy was developed by Eli Lilly Company and Boehringer Ingelheim Pharmaceuticals; the companies announced the FDA action in a joint statement.
Sodium glucose cotransporter-2 inhibitors blocks the protein responsible for glucose reabsorption in the excretory system; thus, excess glucose is expelled through the urine. In this combination therapy, the SGLT2 inhibitor complements metformin, a longstanding treatement for T2DM that lowers glucose production in the liver and its reabsorption in the intestines.
FDA’s action is based on findings from earlier clinical trials that involved administration of empagliflozin and metformin in combination, either with or without sulfonyfurea, to treat T2DM. The drug is already available in Europe.
Reference
US FDA approves Synjardy (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes [press release]. http://www.prnewswire.com/news-releases/us-fda-approves-synjardy-empagliflozinmetformin-hydrochloride-tablets-for-adults-with-type-2-diabetes-300134171.html Ridgefield, CT, and Indianapolis, IN: PRNewswire; August 27, 2015.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen